PROCEPT BioRobotics (PRCT) director awarded new stock options and RSUs

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp director Dan Puckett received new equity awards. On March 5, 2026, he was granted stock options for 8,897 shares at an exercise price of $0.00 per share and 5,476 shares of common stock in the form of restricted stock units.

One-third of the stock options and one-third of the RSUs are scheduled to vest on March 5, 2027, with the remaining two-thirds of each award vesting in equal annual installments over the following two years, subject to his continued service with the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider PUCKETT DAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,897	$0.00	--
Grant/Award	Common Stock	5,476	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,897 shares (Direct); Common Stock — 5,476 shares (Direct)

Footnotes (1)

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on March 5, 2027, with one-third of the remaining RSUs vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. This Stock Option was granted on March 5, 2026, and one-third of the shares subject to the Stock Option shall vest on March 5, 2027, with one-third of the remaining shares subject to the Stock Option vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PUCKETT DAN

(Last) (First) (Middle)

150 BAYTECH DR.

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		5,476(1)	A	$0	5,476	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.35	03/05/2026		A		8,897		(2)	03/04/2036	Common Stock	8,897	$0	8,897	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on March 5, 2027, with one-third of the remaining RSUs vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date.

2. This Stock Option was granted on March 5, 2026, and one-third of the shares subject to the Stock Option shall vest on March 5, 2027, with one-third of the remaining shares subject to the Stock Option vesting annually on each of the second and third anniversary thereof, subject to the Reporting Person continuing as a service provider through such date.

Remarks:

	/s/ Jonathan Stone, Attorney-in-Fact for Dan Puckett	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PROCEPT BioRobotics (PRCT) director Dan Puckett report?

Dan Puckett reported equity award grants from PROCEPT BioRobotics, not open-market trades. He received stock options and restricted stock units as part of his director compensation, increasing his direct holdings through awards with multi-year vesting tied to ongoing service with the company.

How many stock options did Dan Puckett receive from PROCEPT BioRobotics (PRCT)?

He received a grant of stock options covering 8,897 shares of PROCEPT BioRobotics common stock. These options were granted on March 5, 2026, with one-third vesting on March 5, 2027 and the remaining shares vesting in equal annual installments over the next two years.

What restricted stock unit (RSU) award did PROCEPT BioRobotics (PRCT) grant to Dan Puckett?

PROCEPT BioRobotics granted 5,476 restricted stock units to director Dan Puckett. Each RSU represents a contingent right to receive one share of common stock, subject to a three-year vesting schedule and his continued service as a provider to the company through each vesting date.

What is the vesting schedule for Dan Puckett’s PROCEPT BioRobotics (PRCT) RSUs?

One-third of the RSUs vest on March 5, 2027. The remaining RSUs then vest in equal annual installments on the second and third anniversaries of that date, provided he continues as a service provider to PROCEPT BioRobotics through each respective vesting date.

How do Dan Puckett’s PROCEPT BioRobotics (PRCT) stock options vest over time?

The stock options granted on March 5, 2026 vest over three years. One-third of the option shares vest on March 5, 2027, with one-third of the remaining shares vesting on each of the second and third anniversaries, contingent on his continued service with the company.

Did Dan Puckett buy or sell PROCEPT BioRobotics (PRCT) shares on the market?

The reported transactions are equity award grants, not market purchases or sales. He acquired stock options and restricted stock units at a reported price of $0.00 per share as part of his compensation, subject to multi-year vesting based on continued service.